Immunovant, Inc. (IMVT) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IMVT Revenue Growth
IMVT Revenue Analysis (2018–2025)
As of May 6, 2026, Immunovant, Inc. (IMVT) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2026) recorded $0 in revenue.
Looking at the longer-term picture, IMVT's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including ARDX (+18.2% YoY), RCUS (+67.4% YoY), and DAWN (+20.6% YoY). Compare IMVT vs ARDX →
IMVT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IMVTCurrent | $0 | - | - | - | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 DAWN | $158M | +20.6% | - | -80.8% |
IMVT Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-438,152,000 | - |
| 2024 | $0 | - | $0 | - | $-270,209,000 | - |
| 2023 | $0 | - | $0 | - | $-208,276,000 | - |
| 2022 | $0 | - | $0 | - | $-156,033,000 | - |
| 2021 | $0 | - | $0 | - | $-108,117,000 | - |
| 2020 | $0 | - | $-21,000 | - | $-59,678,000 | - |
| 2019 | $0 | - | $0 | - | $-450 | - |
| 2018 | $0 | - | $0 | - | $-136,740,000 | - |
See IMVT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMVT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IMVT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIMVT — Frequently Asked Questions
Quick answers to the most common questions about buying IMVT stock.
Is IMVT's revenue growth accelerating or slowing?
IMVT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is IMVT's long-term revenue growth rate?
Immunovant, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is IMVT's revenue distributed by segment?
IMVT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.